Op deze pagina vindt u de relevante studies met betrekking tot Quinsair®.
- Elborn, J. S., Geller, D. E., Conrad, D., Aaron, S. D., Smyth, A. R., Fischer, R., ... & Morgan, E. E. (2015). A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.Journal of Cystic Fibrosis,14(4), 507-514. Klik hier voor de studie.
- Elborn, J. S., Flume, P. A., Cohen, F., Loutit, J., & VanDevanter, D. R. (2016). Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis,15(5), 634-640. Klik hier voor de studie.
- King, P., Lomovskaya, O., Griffith, D. C., Burns, J. L., & Dudley, M. N. (2010). In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.Antimicrobial agents and chemotherapy,54(1), 143-148. Klik hier voor de studie.
